A comprehensive review of biomarkers in psoriasis

Clinical and Experimental Dermatology

Volumn 34, Issue 6, 2009, Pages 658-663

  Rashmi, R ^a   Rao, K S J ^b   Basavaraj, K H ^a  

^a JSS MEDICAL COLLEGE   (India)

^b INDICASAT   (Panama)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; CALGRANULIN A; CATALASE; CONNEXIN 26; CYTOKERATIN 1; CYTOKERATIN 10; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; FILAGGRIN; GLUTATHIONE PEROXIDASE; HAPTOGLOBIN; HEAT SHOCK PROTEIN 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 1; INTERLEUKIN 18; INVOLUCRIN; MALONALDEHYDE; NERVE GROWTH FACTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL X; PROTEIN P53; SOMATOSTATIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; KERATINOCYTE; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; REVIEW; SKIN INFLAMMATION;

BIOLOGICAL MARKERS; FREE RADICALS; GENE EXPRESSION; HUMANS; KERATINOCYTES; OXIDATIVE STRESS; PSORIASIS; UP-REGULATION;

EID: 68249155540     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03410.x     Document Type: Review

References (39)

1. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004 15 : 1677 89.
2. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 69 : 89 95.
3. de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008 35 : 1443 8.
4. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004 150 : 917 28. (Pubitemid 38903524)
5. Schon MP, Boehncke WH. Medical progress: psoriasis. N Engl J Med 2005 352 : 1899 912.
6. Piskin S, Gurkok F, Ekuklu G et al. Serum lipid levels in psoriasis. Yonsei Med J 2003 44 : 24 6.
7. Saraceno R, Kleyn CE, Terenghi G et al. The role of neuropeptides in psoriasis. Br J Dermatol 2006 155 : 876 82.
8. Matsushita Y, Shimada Y, Kawara S et al. Autoantibodies directed against the protease inhibitor calpastatin in psoriasis. Clin Exp Immunol 2005 139 : 355 62.
9. Tekin NS, Tekin IO, Barut F et al. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007 2007 : 78454.
10. Yildirim M, Inaloz HS, Baysal V et al. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003 17 : 34 6.
11. de Jongh GJ, Zeeuwen PL, Kucharekova M et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005 125 : 1163 73.
12. Grove T, Mulfinger L. The pathogenesis of psoriasis: biochemical aspects. J Young Invest 2001 4. Available at: http://www.jyi.org/volumes/volume4/issue1/ articles/grove.html (accessed 22 May 2009).
13. Schroeder WT, Thacher SM, Stewart-Galetka S et al. Type I kerantinocyte transglutaminase: expression in human skin and psoriasis. J Invest Dermatol 1992 99 : 27 34.
14. Seung NR, Park EJ, Kim CW et al. Comparison of expression of heat-shock protein 60, Toll-like receptors 2 and 4, and T-cell receptor γδ in plaque and guttate psoriasis. J Cutan Pathol 2007 34 : 903 11.
15. Curry JL, Qin JZ, Bonish B et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003 127 : 178 86.
16. Lucke T, Choudhry R, Thom R et al. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium. J Invest Dermatol 1999 112 : 354 61.
17. Lemaitre G, Sivan V, Lamartine J et al. Connexin 30, a new marker of hyperproliferative epidermis. Br J Dermatol 2006 155 : 844 6.
18. Nanney LB, Stoscheck CM, Magid M, King LE Jr. Altered [125i]epidermal growth factor binding and receptor distribution in psoriasis. Biull Eksp Biol Med 1993 115 : 618 20.
19. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991 138 : 129 40.
20. Kagramanova AT, Tishchenko LD, Berezov TT. The ornithine decarboxylase activity of the epidermis in psoriasis as a biochemical index of the hyperproliferative process. Biull Eksp Biol Med 1993 11 : 618 20 S
21. Raynaud F, Evain-Brion D, Keryer G. MAP kinase abnormalities in hyperproliferative cultured fibroblasts from psoriatic skin. J Invest Dermatol 1998 110 : 872 9.
22. Duvic M, Asano AT, Hagar C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazaroter. J Am Acad Dermatol, 1998 4 : S129 33.
23. Blessing M, Schirmacher P, Kaiser S. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 1996 135 : 227 39.
24. Wrone-Smith T, Mitra RS, Thompson CB et al. Keratinocytes derived from psoriatic plaques are resistant to apoptosis compared with normal skin. Am J Pathol 1997 151 : 1321 9.
25. Batinac T, Zamolo G, Hadzisejdic I et al. Expression of Bcl-2 family proteins in psoriasis. Croat Med J 2007 4 : 319 26.
26. Wrone-Smith T, Johnson T, Nelson B et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995 146 : 1079 88.
27. Tomkova H, Fujimoto W, Arata J. Expression of bcl-2 antagonist bak in inflammatory and neoplastic skin diseases. Br J Dermatol 1997 137 : 703 8.
28. Tomkova H, Fujimoto W, Arata J. Expression of the bcl-2 homologue Bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur J Dermatol 1998 8 : 256 60.
29. Yamamoto T, Nishioka K. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy. Skin Pharmacol Appl Skin Physiol 2003 16 : 50 8.
30. Gudjonsson JE, Johnston A, Sigmundsdottir H et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004 135 : 1 8.
31. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 445 : 866 73.
32. Nestle FO, Conrad C, Tun-Kyi A et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005 202 : 135 43.
33. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provides new therapeutic opportunities. J Clin Invest 2004 113 : 1664 75.
34. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 445 : 648 51.
35. Flisiak I, Klepacki A, Chodynicka B. Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006 11 : 194 200.
36. Pietrzak A, Lecewicz-Torun B, Chodorowska G et al. Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score. Acta Derm Venereol 2003 83 : 262 5.
37. Bevelacqua V, Libra M, Mazzarino MC et al. Long pentraxin 3. A marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006 18 : 415 23.
38. Steinhoff M, Staonder S, Seeliger S et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003 139 : 1479 88.
39. Raychaudhuri SP, Jiang WY, Farber EM. Psoriatic keratinocytes express high levels of nerve growth factor. Acta Derm Venereol 1998 78 : 84 6.